PF
PFGTF.US Pacific Edge Limited
- Market cap
- USD 168M
- P/E
- -
- P/B
- 28.27x
- ROE
- -335.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Mar 2026.
Is PFGTF.US undervalued?
Graham numberThe Graham number of Pacific Edge Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Pacific Edge Limited fundamental analysis
No fundamental analysis for Pacific Edge Limited yet.
Pacific Edge Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Pacific Edge Limited
Pacific Edge Limited, a cancer diagnostics company, engages in development and commercialization of bladder cancer diagnostic and prognostic tests for patients. It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the stratification and surveillance of bladder cancer. It also develops Cxbladder Triage, a frontline diagnostic product that helps de-intensify clinical work-up in microhematuria patients; Cxbl…
Full company profilePacific Edge Limited financial statements
Pacific Edge Limited annual financial statements (NZD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 2.24M | 3.40M | 3.82M | 4.37M | 2.15M | 11.4M | 19.6M | 26.1M | 21.8M | 11.6M |
| Gross Profit | -742K | -1.52M | -973K | -1.22M | -3.69M | 4.56M | 9.60M | 13.5M | 21.8M | -945K |
| Operating Income | -16.8M | -21.8M | -19.2M | -19.8M | -22.6M | -22.2M | -34.4M | -45.9M | -34.1M | -38.2M |
| EBITDA | -15.4M | -20.9M | -19.0M | -18.4M | -15.4M | -21.8M | -32.8M | -36.9M | -31.6M | -35.6M |
| Net Income | -15.8M | -19.6M | -17.9M | -18.9M | -14.2M | -19.8M | -27.0M | -29.5M | -29.9M | -36.1M |
| EPS | -0.04 | -0.04 | -0.03 | -0.03 | -0.02 | -0.03 | -0.03 | -0.04 | -0.04 | -0.04 |
| Balance Sheet | ||||||||||
| Total Assets | 23.6M | 19.7M | 16.6M | 19.3M | 31.2M | 124M | 97.1M | 65.4M | 37.0M | 17.8M |
| Total Liabilities | 2.73M | 3.03M | 2.66M | 4.82M | 6.08M | 7.43M | 8.71M | 10.8M | 10.9M | 7.01M |
| Shareholders' Equity | 20.8M | 16.6M | 13.9M | 14.5M | 25.1M | 117M | 88.4M | 54.6M | 26.1M | 10.8M |
| Cash & Short-term Investments | 14.6M | 5.24M | 12.8M | 14.8M | 23.1M | 105M | 77.8M | 50.3M | 22.6M | 7.85M |
| Total Debt | - | 99.0K | 84.0K | 1.55M | 2.88M | 1.92M | 1.22M | 4.07M | 2.90M | 1.30M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -17.8M | -18.1M | -17.5M | -15.4M | -13.6M | -17.6M | -25.6M | -25.8M | -24.7M | -32.3M |
| Capital Expenditure | 479K | 335K | 156K | 183K | 378K | 1.13M | 2.91M | 1.50M | 1.27M | 118K |
| Free Cash Flow | -18.3M | -18.4M | -17.7M | -15.6M | -13.9M | -18.7M | -28.5M | -27.1M | -26.0M | -32.4M |
| Ratios | ||||||||||
| ROE | -75.8% | -118.1% | -128.8% | -130.2% | -56.6% | -17.0% | -30.5% | -54.1% | -114.8% | -335.7% |
| ROA | -67.0% | -99.9% | -108.2% | -97.7% | -45.6% | -16.0% | -27.8% | -45.1% | -80.8% | -203.3% |
| Net Profit Margin | -704.1% | -577.8% | -469.4% | -432.2% | -660.9% | -172.9% | -137.5% | -113.3% | -137.0% | -311.1% |
| Debt to Equity | - | 0.01x | 0.01x | 0.11x | 0.11x | 0.02x | 0.01x | 0.07x | 0.11x | 0.12x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Pacific Edge Limited dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | USD 97.0K | 0.00 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 63:59 on Dec 13, 2019.
Who owns Pacific Edge Limited
- Insiders 19.72%
- Institutions 29.64%
- Public & others 50.64%
- Shares outstanding 1.24B
- Free float 854M
Pacific Edge Limited company profile
- Company name
- Pacific Edge Limited
- Ticker
- PFGTF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- March
- Address
- Centre for Innovation, Dunedin, New Zealand, 9016
- Phone
- 64 3 577 6733
- Website
- pacificedgedx.com
About Pacific Edge Limited
Pacific Edge Limited, a cancer diagnostics company, engages in development and commercialization of bladder cancer diagnostic and prognostic tests for patients. It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the stratification and surveillance of bladder cancer. It also develops Cxbladder Triage, a frontline diagnostic product that helps de-intensify clinical work-up in microhematuria patients; Cxbladder Detect, which improve practice workflow and efficiency in urological care; Cxbladder Triage Plus, a non-invasive surveillance alternative that can reduce the burden of repeated cystoscopy in patients; and Cxbladder Monitor, a non-invasive surveillance alternative that reduces the burden of repeated cystoscopy in patients with a recurrent non-muscle invasive bladder cancer. In addition, the company is developing products for bladder, gastric, colorectal and endometrial cancers, and melanoma. Pacific Edge Limited was incorporated in 2001 and is headquartered in Dunedin, New Zealand.
Pacific Edge Limited management
10- Dr. Peter MeintjesChief Executive Officer
- Mr. Grant GibsonChief Financial Officer
- Mr. Darrell MorganChief Operating Officer
- Dr. Justin HarveyChief Technology Officer
- Prof. Parry Guilford Ph.D.Chief Scientific Officer & Member of Scientific Advisory Board
- Zoe O'DonnellGlobal Head of People & Culture
- Glen CostinPresident of Asia Pacific
- Dr. Tamer AboushwarebChief Medical Officer
- Mr. James J. Vaughn R.Ph.Chief Commercial Officer · born 1963
- Mr. Willy IglesiasChief Digital Officer